Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0720

+2.9%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: boomertree2	10/3/2014 9:03:36 AM
	Read Replies (1) of 13111

Immunotherapy Given Breakthrough Status In Melanoma. In continuing coverage, Forbes (10/2) reports Bristol Myers Squibb recently disclosed major developments regarding its immunotherapy medicine nivolumab, noting that the FDA has approved a “breakthrough status to the drug for advanced melanoma and has agreed to review the license application on priority basis.” The review is expected to be completed by the end of March 2015. Also, the European Medicines Agency is going to speed up “the review and assessment of nivolumab for treatment of advanced melanoma as well.”

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next